Saccharomyces boulardii CNCM I-745 protects against small intestinal injury in a model of gliadin-peptide-induced sterile inflammatory enteropathy - Report - MDSpire

Saccharomyces boulardii CNCM I-745 protects against small intestinal injury in a model of gliadin-peptide-induced sterile inflammatory enteropathy

  • By

  • Aluminé Lezcano

  • Emanuel Miculan

  • Geronimo Ducca

  • Carolina Ruera

  • María Luz Iribarren

  • Philippe Tixador

  • Xavier Roux

  • Fernando Gabriel Chirdo

  • July 6, 2026

  • 0 min

Share

Clinical Report: Saccharomyces boulardii CNCM I-745 Mitigates Small Intestinal Damage

Overview

The probiotic yeast Saccharomyces boulardii CNCM I-745 significantly mitigated small intestinal damage and inflammation in a gliadin-peptide-induced model of sterile inflammatory enteropathy in mice.

Background

Inflammation of the small intestine can lead to serious complications such as malabsorption and chronic diarrhea. Understanding the effects of probiotics in non-infectious conditions, particularly in the small intestine, is crucial for developing effective therapeutic strategies.

Data Highlights

ParameterResults
Villus-height-to-crypt-depth ratioRestored with Sb treatment
Inflammatory marker Cxcl10Upregulation prevented by Sb
Caspase-1 activationAttenuated by Sb
Cell deathReduced with Sb treatment

Key Findings

  • Saccharomyces boulardii CNCM I-745 improved histological parameters in the small intestine.
  • Concomitant Sb treatment restored the villus-height-to-crypt-depth ratio.
  • Inflammatory marker Cxcl10 expression was upregulated by gliadin peptide but prevented by Sb.
  • Western blot analysis showed that Sb attenuated caspase-1 activation.
  • Cell death induced by gliadin peptide was reduced with Sb treatment.

Clinical Implications

Further clinical evaluation in conditions such as celiac disease is warranted to explore the therapeutic potential of Saccharomyces boulardii CNCM I-745.

Conclusion

Saccharomyces boulardii CNCM I-745 demonstrates significant protective effects against small intestinal inflammation and damage in a murine model.

Related Resources & Content

  1. Frontiers in Immunology, 2026 -- Saccharomyces boulardii CNCM I-745 protects against small intestinal injury in a model of gliadin peptide-induced sterile inflammatory enteropathy
  2. European Society for the Study of Coeliac Disease 2025 Updated Guidelines on the Diagnosis and Management of Coeliac Disease in Adults. Part 1: Diagnostic Approach - PubMed
  3. The Journal of Infectious Diseases — The Role of Nutrition in Clostridioides difficile Infections: A Comprehensive Review
  4. The Journal of Infectious Diseases — MicroRNA miR-27a-5p Reduces Intestinal Inflammation Induced by Clostridioides difficile Flagella by Regulating the Nuclear Factor–κB Signaling Pathway
  5. Frontiers in Immunology — Microbiota metabolite butyrate alleviates intestinal inflammation associated with enhanced autophagy-related signaling in DSS-induced colitis
  6. Journal of Gastroenterology — Immune Reactions to Dietary Antigens in Patients with Crohn's Disease and Mice with Induced Colitis
  7. European Society for the Study of Coeliac Disease 2025 Updated Guidelines on the Diagnosis and Management of Coeliac Disease in Adults. Part 1: Diagnostic Approach - PubMed
  8. Frontiers | Saccharomyces boulardii CNCM I-745 protects against small intestinal injury in a model of gliadin peptide-induced sterile inflammatory enteropathy
  9. Efficacy and safety of Saccharomyces boulardii as adjunct therapy with Vancomycin in treating Clostridioides difficile infection: A randomized controlled trial | Scientific Reports

Original Source(s)

Saccharomyces boulardii CNCM I-745 protects against small intestinal injury in a model of gliadin-peptide-induced sterile inflammatory enteropathy

  • by Aluminé Lezcano, Emanuel Miculan, Geronimo Ducca, Carolina Ruera, María Luz Iribarren, Philippe Tixador, Xavier Roux, Fernando Gabriel Chirdo

  • July 6, 2026

Related Content

Hospital Prices Posted. Few Patients Look.

Federal rules require hospitals to post prices so patients can shop. Instead, insurers and providers use the data to negotiate what they get paid.

Anxiety Linked to Gut Disease Trajectories

Longitudinal electronic health record data are used to examine temporal relationships between psychiatric and gastrointestinal diagnoses.

Side Effects: Four Studies Worth Passing On

Kissing celiacs, Ozempic genes, Viagra for the brain, and a UTI test that actually works. This week's evidence is weird, useful, and worth your time.